Literature DB >> 14561187

Inflammation and Parkinson's disease.

Christophe Wersinger1, Anita Sidhu.   

Abstract

Numerous recent findings indicate the possible involvement of an immune mechanism in the pathogenesis of neurodegeneration. The immune reaction could either act as a primary event, generating changes leading to cell death, or could be a secondary response to neuronal injury. In various neurodegenerative disorders such as Alzheimer's, Huntington's or Pick's disease, Down's syndrome, multiple sclerosis and the AIDS-dementia complex, the inflammatory pathomechanism is strongly supported by experimental and clinical studies. Such inflammatory mechanisms have also been postulated in Parkinson's disease (PD). This review summarizes some generalities about inflammation and immune reactions in the context of the brain, and provides clinical, epidemiological and experimental data showing that inflammation and immunity, or even auto-immunity, could be implicated in PD, either in its initial step or in its progression. Different experimental models useful for studying the role(s) of inflammation and (auto)immunity in the neurodegenerative process of the dopaminergic neurons in PD are examined. The major similarities and differences between PD and other neurodegenerative disorders are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14561187     DOI: 10.2174/1568010023344580

Source DB:  PubMed          Journal:  Curr Drug Targets Inflamm Allergy        ISSN: 1568-010X


  15 in total

Review 1.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 2.  Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism.

Authors:  Weihong Feng; Huailing Wei; Geng Tao Liu
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 3.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

4.  Accumulation of phosphorylated tyrosine hydroxylase into insoluble protein aggregates by inhibition of an ubiquitin-proteasome system in PC12D cells.

Authors:  Ichiro Kawahata; Hirofumi Tokuoka; Hasan Parvez; Hiroshi Ichinose
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

5.  Reproductive and neurological Quaking(viable) phenotypes in a severe combined immune deficient mouse background.

Authors:  Tammy A Tucker; Jean A Kundert; Alla A Bondareva; Edward E Schmidt
Journal:  Immunogenetics       Date:  2005-04-08       Impact factor: 2.846

Review 6.  Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

Authors:  Barbara Sperner-Unterweger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglodi; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-04-17       Impact factor: 3.911

8.  Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.

Authors:  Tamy C Frank-Cannon; Thi Tran; Kelly A Ruhn; Terina N Martinez; John Hong; Marian Marvin; Meagan Hartley; Isaac Treviño; Daniel E O'Brien; Bradford Casey; Matthew S Goldberg; Malú G Tansey
Journal:  J Neurosci       Date:  2008-10-22       Impact factor: 6.167

Review 9.  Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors:  Malú G Tansey; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

10.  Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.

Authors:  Howard J Federoff
Journal:  Neurotox Res       Date:  2009-04-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.